Aquestive Therapeutics (AQST) announced that the U.S. Food and Drug Administration, FDA, has accepted the Company’s New Drug Application, NDA, for Anaphylm in the treatment of Type 1 allergic reactions, including anaphylaxis, and has assigned a Prescription Drug User Fee Act, PDUFA, target action date of January 31, 2026. The FDA reiterated that it may decide to conduct an Advisory Committee meeting for the approval of Anaphylm. If approved by the FDA, Anaphylm would be the first and only orally delivered epinephrine option for the treatment of severe allergic reactions in the United States.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics Holds Annual Stockholders Meeting
- Aquestive Therapeutics Prepares for FDA Approvals and Launches
- Aquestive Therapeutics assumed with an Outperform at Oppenheimer
- Aquestive Therapeutics price target lowered to $7 from $15 at Oppenheimer
- Aquestive Therapeutics’ Earnings Call: Mixed Outlook
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue